In the race to gain approval for a drug to treat NASH, or non-alcoholic steatohepatitis, Intercept has always been at the head of the pack, ever since the National Institutes of Health-led FLINT trial turned up a surprise positive finding six years ago.
Because so many rivals have suffered setbacks, that leading position has not changed. The latest delay won’t necessarily allow others to gain an upper hand either.
